Endo Gets 180-Day Market Exclusivity For OxyContin

Law360, New York (March 24, 2004, 12:00 AM EST) -- Endo Pharmaceuticals said Wednesday it would get 180-day market exclusivity for its generic versions of 10 milligram, 20 mg. and 40 mg. of the painkiller OxyContin.

Endo and Israeli drug maker Teva Pharmaceutical Industries on Tuesday evening received U.S. Food and Drug Administration approval for generic versions of the drug.

Privately held Purdue Pharma, which makes the brand-name version, has sued several companies that are planning to launch generic versions of the drug.

The Connecticut-based drug maker has filed an appeal to the Federal Circuit Court...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.